Drugs / Flu-M Tetra
Flu-M Tetra
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05308212 | Mar → Jul 2021 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05739474 | Jan 2022 → Jun 2023 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLU-M Tetra | “The goal of this clinical trial is to assess tolerability, reactogenicity, safety and immunogenicity of the Flu-M Tetra vaccine as compared to the VaxigripTetra vaccine in...” NCT05739474 ↗2“Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in...” NCT05308212 ↗ |
| Known as | Flu-M Tetra Inactivated Split Quadrivalent Influenza Vaccine | “Flu-M Tetra Inactivated Split Quadrivalent Influenza Vaccine” NCT05739474 ↗ |
| Modality | Vaccine | “inactivated split influenza vaccine” NCT05308212 ↗ |
| Route | Intramuscular | “solution for intramuscular injection” NCT05308212 ↗ |